TropiAid: Natural Ointments & Liniments
TropiAid: Natural Ointments & Liniments
TropiAid Products
1.1.1
Liniment
The physical appearance of liniment is a transparent and liquid-like.
It contains contains camphor, banana oil, menthol, peppermint, borneol
and eucalyptus oil. This formulation is applicable to the two variants of
Liniment, regular and massage. These are to 50ml and 100ml containing
each variant and an inhaler which contains 2ml massage formulations. The
banana oil has a higher percentage to suggest quick relief. The massage
liniment variety, however, contains higher composition of camphor and
menthol content compared to regular emphasize the distinction between
the regular and massage.
The inhaler also contains similar content with massage yet, packed
into 2ml packaging compared to massage.
1.1.2
Ointment
The ointment product appears to be a topical cream type medicine.
It is composed of banana oil, beeswax, citronella oil and Olive oil. Ointment
is further divided into three variants, the antifungal, antipruritic, and
corticosteroid. The three variants vary on the percent content of banana oil
for each variant. Antifungal heals skin irritations like an-an, bun-I, and
athlete's foot and prevents further infection caused by bacteria and fungi.
Antipruritic soothes itchiness and heals skin damaged caused by scratches
due to bug bites and the like. The Corticosteroids is specially formulated to
cure skin diseases like Psoriasis and Eczema. It also contains the highest
banana oil content among the three variants, to improve effectiveness.
2|Page
2 Marketing Plan
2.1
Potential Market
Primarily, the potential market includes the all households in the Philippine
population. Also, the market should belong to an ABC income level living in urbanized
areas. (See Appendix D-1: Forecasted Potential Market (2014-2018) Philippines)
2.2
Target Market
Currently, the ointments and liniments industry are composed of highly established
brands of highly competitive companies. In this light, the proponents decided enter the
industry as a market niche.
Generally, the target market focuses only in Mindanao and Cebu. Bringing the
name of its being natural, it could grab the opportunity to attract those who are interested
and preferred to buy natural made remedies. The following are the specifications of the
target market:
Households
On the long run, the proponents may extend the market to doctors, specifically
dermatologists and general doctors, who are experts on skin treatments and body pain
remedies.
2.3
(2012) is 915,296. Having an average population growth rate of 1.83 percent per
year from 2014 to 2018, from the current, it will increase to 949,381 in 2014 and
further increase to 1,020,206 in 2018. (See Appendix D-2 and D-3: Forecasted
Potential Market (2014-2018) Mindanao and Cebu)
3|Page
Target Market
Davao Region
Target Market
2014
2015
949,848
967,610
249,345
254,008
2016
985,704
258,758
2017
1,004,137
263,597
2018
1,022,914
268,526
22,749
23,175
23,608
24,050
24,499
8,159
8,312
8,467
8,626
5,719
5,826
5,935
6,046
6,159
Zamboanga Peninsula
10,058
10,246
10,437
10,632
Caraga
10,934
11,138
11,346
11,558
28,468
3.00%
4.70%
58,151
6.01%
5.64%
19,498
78,736
7.99%
6.77%
19,863
80,209
7.99%
8.12%
20,234
81,709
7.99%
9.75%
Northern Mindanao
SOCSKSARGEN
Cebu
Total Captured Market
Percentage Captured
Market Share
The proceeding tables show the demand in unit volume of the liniments
and ointments. An assumption volume of variant was made during calculating
process. For liniment products, it is assumed to have the following percentage:
inhalers have only one variant, the massage, while the other two sizes have both
with 60% of the volume goes to regular while the other 40% are for the massage
variants. For the ointment products, it is assumed to have the following percentage:
35%, 35%, and 30% for the antifungal cream, antipruritic, and corticosteroids
respectively. The percent of the total projected market in terms of unit volume are
0.10%, 0.12%, 0.14%, 0.17%, and 0.21% for years 2014, 2015, 2016, 2017, and
2018 respectively.
For the liniment category, a 10% volume is allotted for the inhalers with an
annual increase of 10% to intensify its sales. The rest of the 90% is divided among
the other two sizes, 47% for the 50ml and 43% for the regular one. This percentage
is used in allocating the demand ratio for the inhaler and 50 and 100ml bottles.
The unit demand of each month of the year differs due to the following
certain events. For the liniments, the peak periods are during months of January,
June, July, and December with 10% of the annual demand is shown per month.
The factor behind this is that June and July are rainy seasons, thus an expected
demand for these types of medicines. Also, since January and December are cold
4|Page
2014
2015
2016
2017
2018
Massage Massage Massage Massage Massage
608
774
1,266
1,563
1,910
486
619
1,013
1,250
1,528
547
697
1,139
1,407
1,719
431
544
886
1,094
1,337
431
544
886
1,094
1,337
615
777
1,266
1,563
1,910
620
787
1,270
1,563
1,910
372
472
762
938
1,146
496
630
1,016
1,250
1,528
564
708
1,151
1,407
1,719
376
472
767
938
1,146
627
787
1,279
1,563
1,910
6,173
7,811
12,701
15,630
19,100
2014
2015
2016
2017
2018
Regular Massage Regular Massage Regular Massage Regular Massage Regular Massage
764
509
972
648
1,590
1,060
1,963
1,308
2,398
1,599
611
407
778
518
1,272
848
1,570
1,047
1,919
1,279
687
458
875
583
1,431
954
1,766
1,178
2,159
1,439
541
361
683
455
1,113
742
1,374
916
1,679
1,119
541
361
683
455
1,113
742
1,374
916
1,679
1,119
773
515
976
651
1,590
1,060
1,963
1,308
2,398
1,599
779
519
988
659
1,595
1,063
1,963
1,308
2,398
1,599
467
312
593
395
957
638
1,178
785
1,439
959
623
415
791
527
1,276
851
1,570
1,047
1,919
1,279
709
472
890
593
1,445
964
1,766
1,178
2,159
1,439
472
315
593
395
964
642
1,178
785
1,439
959
787
525
988
659
1,606
1,071
1,963
1,308
2,398
1,599
7,754
5,169
9,810
6,538
15,952
10,635
19,628
13,084
23,984
15,988
5|Page
2014
2015
2016
2017
2018
Regular Massage Regular Massage Regular Massage Regular Massage Regular Massage
696
464
886
591
1,448
966
1,788
1,192
2,185
1,457
557
371
709
472
1,159
772
1,431
954
1,748
1,166
626
417
797
531
1,304
869
1,609
1,073
1,967
1,311
493
329
622
415
1,014
676
1,252
835
1,530
1,020
493
329
622
415
1,014
676
1,252
835
1,530
1,020
704
469
889
593
1,448
966
1,788
1,192
2,185
1,457
710
473
901
600
1,453
969
1,788
1,192
2,185
1,457
426
284
540
360
872
581
1,073
715
1,311
874
568
378
721
480
1,162
775
1,431
954
1,748
1,166
646
430
811
540
1,317
878
1,609
1,073
1,967
1,311
430
287
540
360
878
585
1,073
715
1,311
874
717
478
901
600
1,463
976
1,788
1,192
2,185
1,457
7,066
4,709
8,939
5,957
14,532
9,689
17,882
11,922
21,852
14,570
2014
2015
2016
A nti-Fungal A ntipruritic Co rtico stero idA nti-Fungal A ntipruritic Co rtico stero idA nti-Fungal A ntipruritic Co rtico stero id
745
745
745
1,077
1,077
1,077
1,085
1,085
760
768
768
878
10,810
Month
January
February
March
April
May
June
July
August
September
October
November
December
TOTAL
745
745
745
1,077
1,077
1,077
1,085
1,085
760
768
768
878
10,810
638
638
638
923
923
923
930
930
651
658
658
752
9,266
948
948
948
1,360
1,360
1,360
1,377
1,377
964
964
964
1,102
13,675
948
948
948
1,360
1,360
1,360
1,377
1,377
964
964
964
1,102
13,675
813
813
813
1,166
1,166
1,166
1,181
1,181
826
826
826
945
11,721
2017
1,551
1,551
1,551
2,215
2,215
2,215
2,222
2,222
1,556
1,567
1,567
1,791
22,222
1,551
1,551
1,551
2,215
2,215
2,215
2,222
2,222
1,556
1,567
1,567
1,791
22,222
1,329
1,329
1,329
1,899
1,899
1,899
1,905
1,905
1,333
1,343
1,343
1,535
19,048
2018
1,915
1,915
1,915
2,735
2,735
2,735
2,735
2,735
1,915
1,915
1,915
2,188
27,351
1,915
1,915
1,915
2,735
2,735
2,735
2,735
2,735
1,915
1,915
1,915
2,188
27,351
1,641
1,641
1,641
2,344
2,344
2,344
2,344
2,344
1,641
1,641
1,641
1,875
23,443
2,340
2,340
2,340
3,342
3,342
3,342
3,342
3,342
2,340
2,340
2,340
2,674
33,424
2,340
2,340
2,340
3,342
3,342
3,342
3,342
3,342
2,340
2,340
2,340
2,674
33,424
2,005
2,005
2,005
2,865
2,865
2,865
2,865
2,865
2,005
2,005
2,005
2,292
28,649
6|Page
Marketing Strategy
2.4.1
Marketing Objectives
Tropical Pharmaceutical Inc. has the following list of objectives for TropiAid
2.4.2
Positioning Strategies
[Link] Objective
7|Page
2.4.3
Product Strategies
[Link] Objective
Core Product
Tropiaid is a product which relieves skin diseases and body
pains which is made out of natural banana fruit extract. The extract
is clinically proven to have therapeutic effects on the skin due to its
high amount of potassium. Such component does several medicinal
benefits which include relief from pain, swelling, itching, bruising,
wrinkles, and sunburn. (Edwards, 2000) In addition, banana fruits
contain natural anti-inflammatory antiseptic, cooling properties that
can help alleviate or reduce the severity of the eczema and
psoriasis symptoms. (Jewell, 2011)
Product Mix
Liniments
8|Page
Ointments
The ointment product line is further divided into three
9|Page
10 | P a g e
Sizes
The liniment core product has three volumes, inhaler (2ml),
50 ml and 100 ml. For the ointment products, all varieties are
available in 10g packs only. (See Appendixes D and E: Liniment
and Ointment Category Matrices)
A new size is introduced by the proponents, an inhaler which
contains 2ml liniment solution. This innovation answers the demand
for convenience. Also, this packaging integrates an inhaler to
further extend the efficiency in acquiring the products benefits in
curing headaches, which could also be used as a relief in clogged
nose. Now, the solution is one sniff away.
Container
Primary
Generally, the packaging of all the variants shows an
elegant and attractive image that depicts its being premium yet still
considering its natural image. The silver strip incorporated with all
the caps of the products serves as an indication of the product being
premium. The overall impact of integrating the green color serves
as the indication of the product being natural.
With the use of recycled packaging, the company taps Metro
Ace Innovplas Corporation, a plant that manufactures plastic
containers for food, chemicals, and cosmetics for pharmaceutical
companies, various items for agricultural industries, and house
ware items, use of recycled plastics as their main material. With the
11 | P a g e
12 | P a g e
Liniment
The liniment products will be packed in a recyclable plastic
container. It contains a flip top cap, which serves as sealer of the
product; and a body, which is a usual plastic bottle shape that
serves as the container of the liquid formulation.
Below are the images of both front and back parts of the
said container:
Image 6.4. Liniment (50ml and 100ml) - Front
13 | P a g e
Ointment
The ointment product will be packed in a cylindrical shaped
container made out of recycled plastic. It consists of a removable
screw-type cap and a body. The body serves as the container of
the meat of the product.
Below are the packaging concepts of the ointment variants:
Image 6.6. Ointment (10g) - Front
14 | P a g e
Secondary
Each product of TropiAid will be placed in a box that serves
15 | P a g e
Tertiary
Each product sizes of TropiAid product have its own proposed sizes of tertiary
packaging. The tertiary products have the same label that includes the brand name,
product information, safety symbols, and box level capacity.
16 | P a g e
Label
The label holds the product name and the distinctions
Promotion Strategies
[Link] Objectives
Tropical Pharmaceuticals has set the following objectives for its
advertising campaign strategies:
[Link] Advertising
Tropical Pharmaceuticals aims to create awareness among its
targeted market. During the introductory years, intensive advertising and
promotions will be done to make the market aware of the product lines that
the company has to offer. Furthermore, essential benefits will also be
printed as well.
flyers
and
posters
are
forms
of
18 | P a g e
and even some of the older ones, engage with social networking
sites, making online networking advertisements somehow effective.
19 | P a g e
contact to its potential buyers allowing to try and test the product.
This advertisement can be held through an exhibit campaigning a
certain goal, booth stand and product sampling in malls, and
through presenting a testimonial AVR of the product that
encourages the customers to test it.
Television Advertising
Nowadays, even if it is too expensive on having television
LED Advertising
Nowadays, as modern technology offers, LED advertising is
now on its way to become one of the most advantageous forms
of advertising. It is in an advantage and in a most attractive way
of exposure, disseminating information, and introducing the
product since this form of advertisements is usually installed in
high-traffic areas. People passing by will definitely be fascinated
and attracted to see such scenery.
Brochures
Flyers
Posters
LED Advertising
Business Cards
TV Advertising
Product Exhibit
Product Samples
Freebies
Discounts
Trade Promos
Total Costs
2.4.5
2015
63,279.11
26,366.30
21,093.04
105,465.19
5,273.26
158,197.79
91,717.20
104,289.80
34,276.19
5,273.26
615,231.13
2016
64,648.67
26,936.95
21,549.56
107,747.78
5,387.39
215,495.57
161,621.68
93,702.24
106,546.95
35,018.03
5,387.39
844,042.20
2017
65,818.54
27,424.39
21,939.51
109,697.57
5,484.88
219,395.13
164,546.35
95,397.86
108,475.00
35,651.71
5,484.88
859,315.82
2018
66,776.10
27,823.38
22,258.70
111,293.50
5,564.68
222,587.01
166,940.26
96,785.76
110,053.15
36,170.39
5,564.68
871,817.60
Price Strategies
[Link] Objective
[Link] Method
In calculating for the prices, the proponents are guided by the
following pricing methods:
Customer-Based Pricing
The price is based on the customer demand or need for the
Ointment (10g)
P51 to P60
P100 to P150
Price
Competition-Based Pricing
This method will help TropiAid be competitive in terms of
Cost-Based Pricing
The cost in producing and selling the products are identified.
A desired net profit margin is then identified. The total cost and profit
margin are then added to get the selling price.
Price Map
Average Price/ml
Efficascent Oil
1.04
Omega
1.09
Pau Liniment
1.50
0.87
Salonpas Liniment
1.83
Ave/ml
1.27
23 | P a g e
Average Price/g
Canesten Cream
26.50
Nizoral Cream
30.97
Trosyd Cream
30.97
15.47
Ave/g
25.98
Average Price/g
Systral
20.76
Ave/g
20.76
Average Price/g
Aplosyn 10-N
24.80
Baycuten-N
59.90
Dermovate
48.82
Diprolene
47.17
Ave/g
45.17
24 | P a g e
ml
2
50
100
Variety
Regular
Massage
Php/m l
Unit Price
Php/m l
Unit Price
30.00
1.75
87.50
2.00
100.00
1.75
175.00
2.00
200.00
g
10
Anti-Fungal
Php/g
Unit Price
13.00
130.00
Variety
Antipruritic
Php/g
Unit Price
11.00
110.00
Corticosteroid
Php/g
Unit Price
23.00
230.00
25 | P a g e
2014
2015
2016
2017
SRP
Calculated Price
VAT
Price before VAT
Profit Margin
Cost per Unit
SRP
Calculated Price
VAT
Price before VAT
Profit Margin
Cost per Unit
30.00
30.00
3.60
26.40
6.17
20.23
87.50
87.50
10.50
77.00
29.97
47.03
SRP
175.00
Calculated Price
175.00
VAT
21.00
Price before VAT 154.00
Profit Margin
69.16
Cost per Unit
84.84
50m l (Regular)
91.90 96.50 101.40
91.90 96.50 101.40
11.03 11.58 12.17
80.87 84.92 89.23
32.66 35.92 39.52
48.21 49.00 49.71
100m l (Regular)
183.80 193.00 202.70
183.80 193.00 202.70
22.06 23.16 24.32
161.74 169.84 178.38
74.77 81.28 88.40
86.98 88.56 89.98
106.50
106.50
12.78
93.72
43.43
50.29
100.00
100.00
12.00
88.00
40.09
47.91
212.90
212.90
25.55
187.35
96.21
91.14
200.00
200.00
24.00
176.00
90.21
85.79
2018
36.60
36.60
4.39
32.21
11.30
20.91
121.70
121.70
14.60
107.10
55.94
51.16
243.20
243.20
29.18
214.02
121.98
92.04
26 | P a g e
2014
SRP
130.00
Calculated Price
130.00
VAT
15.60
Price before VAT 114.40
Profit Margin
94.98
Cost per Unit
19.42
SRP
110.00
Calculated Price
110.00
VAT
13.20
Price before VAT 96.80
Profit Margin
77.37
Cost per Unit
19.43
SRP
Calculated Price
VAT
Price before VAT
Profit Margin
Cost per Unit
230.00
230.00
27.60
202.40
182.95
19.45
2018
158.20
158.20
18.98
139.22
120.08
19.14
133.80
133.80
16.06
117.74
98.50
19.24
279.70
279.70
33.56
246.14
226.93
19.20
Placement Strategies
[Link] Objective
Tropical Pharmaceuticals aims to penetrate a target market of
about 25% in Mindanao and 78% in Cebu. In order to do so, the products
are distributed depending on the deals arranged between the firm and the
retailers, pharmacies and drugstores, personal care shops, and malls,
corresponding to its locations. Once the deals were closed, it will then be
distributed throughout the branches under those retailers. The strategy for
further distribution to its branches will depend now on the retailers.
Furthermore, the company aims to make the products available and
accessible for their target market.
[Link] Distribution Blueprint
There are several urbanized cities that are considered to be primary
target markets of the firm. These cities are the following:
Mercury
Drugs
Watsons
Malls
Davao
10
12
Tagum
GenSan
Butuan
Surigao
CDO
10
Iligan
Zamboanga
Cebu City
Mandaue
Lapu-Lapu
Talisay
Carcar
Consolacion
The table above shows the areas that can be potential market of
the firm. Pharmacies and drugstore include only those companies who
were known nationwide like Mercury Drug and Rose Pharmacy. For
personal care shops, the data above include only the Watsons personal
care shops. Malls are also included to the potential market.
29 | P a g e
30 | P a g e
2014
75,000.00
320,000.00
360,585.00
144,000.00
899,585.00
Distribution Cost
2015
2016
76,889.28
78,553.40
328,060.92
335,161.17
450,203.63
726,836.84
383,831.27
633,454.60
1,238,985.10 1,774,006.01
2017
79,974.89
341,226.18
877,686.62
890,600.32
2,189,488.00
2018
81,138.40
346,190.52
1,049,004.65
1,059,342.98
2,535,676.54
31 | P a g e
2014
6,173.00
7,754.00
5,169.00
7,066.00
4,709.00
10,810.00
10,810.00
9,262.00
61,753.00
2015
7,811.00
9,810.00
6,538.00
8,939.00
5,957.00
13,672.00
13,672.00
11,722.00
78,121.00
2016
12,701.00
15,952.00
10,635.00
14,532.00
9,689.00
22,223.00
22,223.00
19,048.00
127,003.00
2017
15,630.00
19,628.00
13,084.00
17,882.00
11,922.00
27,353.00
27,353.00
23,441.00
156,293.00
2018
19,100.00
23,984.00
15,988.00
21,852.00
14,570.00
33,424.00
33,424.00
28,647.00
190,989.00
2015
246,046.50
901,539.00
686,490.00
1,642,988.20
1,094,896.60
1,866,228.00
1,579,116.00
2,830,863.00
10,848,167.30
2016
420,403.10
1,539,368.00
1,173,040.50
2,804,676.00
2,136,424.50
3,186,778.20
2,695,649.90
4,830,572.80
18,786,913.00
2017
543,924.00
1,990,279.20
1,516,435.60
3,624,681.40
2,761,135.20
4,119,361.80
3,484,772.20
6,242,338.30
24,282,927.70
2018
699,060.00
2,554,296.00
1,945,739.60
4,652,290.80
3,543,424.00
5,287,676.80
4,472,131.20
8,012,565.90
31,167,184.30
2014
185,190.00
678,475.00
516,900.00
1,236,550.00
941,800.00
1,405,300.00
1,189,100.00
2,130,260.00
8,283,575.00
32 | P a g e
3 Operational Plan
3.1
Technical Specifications
Banana oil is the main ingredient of all TropiAid products. This is integrated with
different natural substances to produce such products. The following are the formulations
of the TropiAid products:
Table 7.1. Liniment and Ointment Formulation
Linim ent Form ulations
Regular Massage
Banana Oil
5.00%
10.00%
Menthol
60.00% 55.00%
Pepperm int 5.00%
5.00%
Cam phor
10.00% 10.00%
Borneol
10.00% 10.00%
Eucalyptus
10.00% 10.00%
3.1.1
Banana Oil
Beesw ax
Other Oils
Citronella Oil
MassageRegular
MassageRegular
Liniment
Liniment
Table 7.3. Raw Materials Requirement per Unit (Liniments) for Years 3, 4 and 5
33 | P a g e
MassageRegular
MassageRegular
Liniment
Liniment
Table 7.4. Raw Materials Requirement per Unit (Ointments) for Years 1 and 2
Secondary Packaging
Ointment Ointment
10g
AF 10 g
AP 10g
C
10g
Tertiary Packaging
1.00
1.00
0.01
1.00
1.00
0.01
1.00
1.00
0.01
Table 7.5. Raw Materials Requirement per Unit (Ointments) for Years 3, 4 and 5
Secondary Packaging
Ointment Ointment
1.00
AP 10g
C 10g
AF 10 g
AP 10g
Tertiary Packaging
C 10g
1.00
0.01
1.00
1.00
0.01
1.00
1.00
0.01
34 | P a g e
Toll Manufacturing
Tropical Pharmaceuticals will produce the products through toll
manufacturing, an arrangement in which another company processes the raw
materials supplied by our company. Specifically, the company will supply the
banana, primary, secondary, and tertiary packaging to the toll manufacturer. After
the whole processing, the company picks up the packed finished goods then
brought and stored in the company warehouse.
If a breach of contract or discontinuity of agreement arises between
Tropical Pharmaceuticals and InventFoods, the firm will then push to deal with
Greenplus Corporation. With this, the alternative plan in line with the change of the
toll manufacturer will then pursue to continue the production. Due to the fact that
shipping a batch of banana fruits would be very expensive, it would be more
practical if the extracted oil from the banana is shipped to the toll manufacturer.
Therefore, the company will outsource Neoteheo International Inc., a company that
provides services in extracting essential oils from banana located in Toril, Davao
City. (For agreement details, see Appendix I and J: Toll Manufacturing Agreement
and SRP)
3.2.1
Operations
After several testing and certification procedures, the tolling operations
start. To further breakdown the processes that the supplied materials undergo, the
following flow chart is followed:
35 | P a g e
Delivery of Banana
Fruit
Stability Test
Distillation
Primary
Packaging
Delivery of Primary
Packaging
Bottling
Secondary
Packaging
Delivery of
Secondary
Packaging
Package in
Secondary Boxes
Tertiary
Packaging
Delivery of Tertiary
Packaging
Package in
Tertiary Boxes
Purchase/Delivery
of Other Oils
Delivery to Office
Storage
The operations enclosed within the red border are the responsibilities of
the toll manufacturer. The remaining operations outside the red border are the
responsibilities of the company.
36 | P a g e
Other Oils
Inventory Management
3.3.1
Finished Goods
2014
7,200
36
69
6,173
958
37
2014
8,900
89
83
7,754
1,063
33
2014
5,900
59
60
5,169
671
31
2014
8,050
161
79
7,066
905
31
2015
958
8,400
42
84
7,811
1,463
35
2015
1,063
10,500
105
103
9,810
1,650
31
2015
671
7,000
70
72
6,538
1,061
30
2015
905
9,600
192
98
8,939
1,468
30
2016
1,463
13,000
65
132
12,701
1,630
31
2016
1,650
16,500
165
168
15,952
2,030
31
2016
1,061
11,000
110
112
10,635
1,314
30
2016
1,468
15,050
301
152
14,532
1,834
31
2017
1,630
16,200
81
164
15,630
2,036
32
2017
2,030
20,200
202
200
19,628
2,402
30
2017
1,314
13,600
136
138
13,084
1,692
32
2017
1,834
18,450
369
187
17,882
2,215
30
2018
2,036
19,200
96
202
19,100
1,934
30
2018
2,402
24,300
243
249
23,984
2,469
31
2018
1,692
14,400
144
168
15,988
(64)
30
2018
2,215
22,050
441
227
21,852
2,186
30
37 | P a g e
2014
5,400
108
52
4,709
639
32
2014
11,900
238
112
10,810
978
31
2014
11,900
238
112
10,810
978
31
2014
10,200
204
100
9,262
838
31
2015
639
6,350
127
66
5,957
966
30
2015
978
14,400
288
142
13,672
1,564
30
2015
978
14,400
288
142
13,672
1,564
30
2015
838
12,350
247
124
11,722
1,342
30
2016
966
10,050
201
100
9,689
1,227
31
2016
1,564
22,850
457
230
22,223
1,961
31
2016
1,564
22,850
457
230
22,223
1,961
31
2016
1,342
19,550
391
200
19,048
1,644
30
2017
1,227
12,300
246
127
11,922
1,478
30
2017
1,961
28,050
561
283
27,353
2,375
30
2017
1,961
28,050
561
283
27,353
2,375
30
2017
1,644
24,050
481
241
23,441
2,012
30
2018
1,478
14,750
295
152
14,570
1,506
31
2018
2,375
34,100
682
342
33,424
2,709
30
2018
2,375
34,100
682
342
33,424
2,709
30
2018
2,012
29,250
585
295
28,647
2,320
30
The firm will use First in First Out (FIFO) in delivering and distributing finished
products to the identified outlets. This method may avoid the damages and spoilage of
materials and products.
Also, the firm considers the Just-in-Time method in the distribution operations. As
stated in the previous chapter, the firm has its own distribution teams. The delivery times
are to be scheduled that is agreeable to both the company and its retailers.
38 | P a g e
Raw Materials
Based on the production plan (see Table 7.6: Production Plan) and raw materials
requirements per unit (see Tables 7.2, 7.3, 7.4, and 7.5: Raw Material Requirements Per
Unit), the company is required to purchase the following quantity of raw materials:
Table 7.7. Annual Raw Materials Requirements
2014
2015
2016
2017
2018
Banana (kg)
Banana Oil (kg)
Citronella Oil (kg)
Primary Packaging (pcs)
240.52
281.31
34.00
-
288.09
336.95
41.15
-
607.08
65.25
-
745.42
80.15
-
890.96
97.45
-
7,200
8,900
5,900
8,050
5,400
11,900
11,900
10,200
7,200
8,900
5,900
8,050
5,400
11,900
11,900
10,200
36
142
637
8,400
10,500
7,000
9,600
6,350
14,400
14,400
12,350
8,400
10,500
7,000
9,600
6,350
14,400
14,400
12,350
42
164
764
13,000
16,500
11,000
15,050
10,050
22,850
22,850
19,550
13,000
16,500
11,000
15,050
10,050
22,850
22,850
19,550
65
244
1,202
16,200
20,200
13,600
18,450
12,300
28,050
28,050
24,050
16,200
20,200
13,600
18,450
12,300
28,050
28,050
24,050
81
296
1,467
19,200
24,300
14,400
22,050
14,750
34,100
34,100
29,250
19,200
24,300
14,400
22,050
14,750
34,100
34,100
29,250
96
308
1,769
39 | P a g e
Suppliers
Table 7.8. Possible Suppliers
Banana
Banana Oil
Citronella Oil
Supplier
Tadeco
Dezhou Tonglin
Chemicals Limited
Liability Company
GuangZhou HuangPu
Gezer Enterprises
Location
Carmen
Shandong, China
Guangdong, China
Bayabas, Cagayan
de Oro City
EFKS General
Merchandise and
Corporate
Giveaw ays
Grace Park, Caloocan
City
1000 kg/day
300 kg/day
2000 kg/month
5000 kg/month
20 kg
50 kg
100 kg
100 kg
16 kg
50 kg
9.00
11.00
100.00
90.00
1300.00
2500.00
On Pick-Up
On Pick-Up
Shipment Cost
at Minimum
Order (in Php)
120.23
85.78
*included in price
*included in price
553.07
1712.00
Total
Price/Unit (in
Php)
15.01
12.72
100.00
90.00
1300.00
2500.00
Maximum
Capacity
Wholesale
Minimum
Order
Price/Unit (in
Php)
Payment
Terms
2 ml
50 m l
100 m l
50 m l
100 m l
10 g
Supplier
Invent Foods
Greenplus
Metroace Innovplas
Location
Calamba, Laguna
80,000 pcs
100,000 pcs
1,000 pcs
1,000 pcs
500
pcs/bag
500
pcs/bag
400
pcs/bag
100
pcs/bag
500
pcs/bag
300 pcs
250 pcs
100 pcs
90.00
100.00
10.00
2.10
2.90
6.50
10.00
2.50
5.00
11.25
On Pick-Up
On Pick-Up
On Pick-Up
On Pick-Up
Shipment Cost
at Minimum
Order (in Php)
85.04
2000.00
75.64
94.51
Total
Price/Unit (in
Php)
90.09
100.20
21.55
28.83
Maximum
Capacity
Wholesale
Minimum
Order
Price/Unit (in
Php)
Payment
Terms
40 | P a g e
Secondary Packaging
Tertiary Packaging
Mindanao
Davao
Cortes Printing Corp. Corrugated Corrugated
Fibreboard
Carton
Supplier
Castaneda Printing
Press
Location
Magallanes, Davao
City
Rizal Extension
Davao City
Sasa,
Davao City
Lanang,
Davao City
10,000 pcs
10,000 pcs
7,000 pcs
5,000 pcs
50 pcs
50 pcs
100 pcs
100 pcs
5.00
6.00
24.00
25.00
On Pick-Up
102.68
94.99
39.89
74.56
7.05
7.90
24.40
25.75
Maximum
Capacity
Wholesale
Minimum
Order
Price/Unit (in
Php)
Payment
Terms
Shipment Cost
at Minimum
Order (in Php)
Total
Price/Unit (in
Php)
On Pick-Up On Pick-Up
Among these suppliers, the company will choose the following companies: Tadeco,
for the banana; GuangZhou HuangPu, for the banana oil; Gezer Enterprises, for the
citronella oil; InventFoods, as our toll manufacturer; Metroace Innovplas Industries, for the
primary packaging; Castaneda Printing Press, for the secondary; and Mindanao
Corrugated Fibreboard, for the tertiary. These are chosen because of their cost
effectiveness. Also, their minimum order quantity can accommodate and adequate to
satisfy Tropical Pharmaceuticals demand.
3.5
Control Measures
41 | P a g e
Compliance Standards
Halal
The company is engaged in toll manufacturing. The toll
Standards Specifications
[Link] Raw Materials
Before sending the raw materials to the manufacturer, the company
ensures the quality of these materials according to the tools presented on
42 | P a g e
Level
Banana
Primary
Secondary
Tertiary
Packaging
Packaging
Packaging
Complete
parts or
Acceptable
Yellow,
segments,
green, no
properly and
black dots
clearly
on its skin
labeled, good
shape and
Standard size
and shape,
properly and
clearly
labeled
Standard size
and shape,
durable,
properly and
clearly
labeled
size
Wet,
Wet,
deformed
deformed
shape, visible
shape, visible
Deformed
scratches and
scratches and
shape, holes
cuts,
cuts,
smudged
smudged
labels,
labels,
mislabeled
mislabeled
Full of black
dots,
Reject
exposed
banana
flesh, moldy
43 | P a g e
Level
Liniment
Ointment
Primary
Secondary
Tertiary
Packaging
Packaging
Packaging
Standard
Acceptabl
e
Standard
Standard
shape and
Standard
Standard
liquid level
weight
size,
size and
shape and
(5%),
(5%),
complete
shape,
size, clear
standard
standard
segments,
clear
labeling,
quality
quality
secured
labeling
durable
locks
Rework
Reject
3.6
Beyond
Beyond
the control
the control
limits of
limits of
acceptabl
acceptabl
e liquid
e weight
level
level
(5%)
(5%)
Loose
threads
(caps),
slightly
deformed
shape
Low
Manageabl
durability,
e blur of
manageabl
label, slight
e blur of
bends/
label, slight
scratches
bends/
scratches
Leak/holes
Smudged
Smudged
Below
Below
, damaged
labels, wet,
labels, wet,
standard
standard
caps,
deformed
deformed
quality
quality
incomplete
shape,
shape,
segments
mislabeled
mislabeled
Waste Disposal
3.6.1
Returned Products
Rejects are the only wastes that the company encounters. Some of these
are returned to the firm due to some defects. These are then returned to the toll
manufacturer for replacement if the toll manufacturer is liable for such damage.
The usual factors of returns are damages upon delivery and damaged labels and
packaging. The damages in which the tolling firm is of responsibility are the
following:
44 | P a g e
Finished products returned from the market and which have left the control
of the toll manufacturer and the firm shall be considered for re-sale, re-labeling or
incorporation in a subsequent batch only after the person responsible for quality
control has critically assessed them. If finished products were not approved for
resale and any doubt arises over quality of the product, they will then be
reprocessed for other uses.
45 | P a g e
Pre-Operating Period
4.1.1
Princess Grace B. Baquirel. (See Appendix K: Owners Resume) They will be one
of the incorporators of the corporation. The project originators will also be the one
who will overlook on all operations, from the pre-operating period to the
actualization of the business operations. Most especially, they are the main
decision makers in the company.
The project promoters of the company will be the proponents of this project.
Since the proponents are the project originators, they are knowledgeable of the
nature of the product, how the product was made, and its profile and benefits.
4.2
Operating Period
The type of business organization of the company will be a corporation. It is a
corporation shared among nine (9) investors. In a corporation, owners have a limited
liability since a corporation is a separate distinct legal entity. Owners of a corporation are
only indebted to the extent of their interest in the corporation. In addition, the corporations
power of succession enables it to enjoy a continuous existence since the shares of its
interest can be transferred from one owner to another. Also, because of limited liability,
ease of transfer of shares and continuity, investors are more attracted to investing in
corporations rather than in sole proprietorships and partnerships. This attraction allows
corporations to raise the capital needed to manage and expand their operations.
46 | P a g e
Internal Organization
4.3.1
Organizational Structure
General Manager
(1)
Administrative
Assistant (1)
Sales and
Marketing Head
(1)
Logistics and
Quality Assurance
Staff (3)
Key Accounts
Executive (4)
Stall Attendants
(4)
4.3.2
Functions
General Manager
o
47 | P a g e
Administrative Assistant
o
Stall Attendants
o
4.3.3
Owners
Tropical Pharmaceuticals is proudly a Dabaweo company. All of the
owners of the corporation reside in the Davao Region. In addition, the percent of
ownership of the incorporators are illustrated below.
48 | P a g e
Percentage of Ownership
Common Stocks,
5%
Baquirel, R., Sr.,
11%
Subang, E. A.,
15%
Baquirel, G., 7%
Baquirel, P. G.,
15%
De Leon, W.,
13%
4.3.4
Management Personnel
Time
Qualifications
Requirements
Recruitment
Resume
Screening
Application
Comprehen
Compensatio
n
Male or Female
Graduate of BS Industrial
Engineering
or
any
General Manager
letter
experience
regarding management of
a company
Positive
referral
from
Organized
Excellent oral and written
Medical
Interview
certificate
NBI
clearance
previous employer
sive Exam
month
P20,000
Monthly
training
Training
Transcript
and
of record
seminars
communication skills
Good moral character
49 | P a g e
Male or Female
Graduate of BS Industrial
Engineering
or
any
8 hours a day
Resume
Screening
Application
Comprehen
experience
regarding position
5 days a week,
letter
referral
from
previous employer
Medical
Interview
certificate
NBI
clearance
Organized
sive Exam
P18,000
Monthly
month
5%
training
Incentives
Training
Transcript
and
of record
seminars
4.3.5
Labor Workforce
Administrative Assistant
2018
2017
2016
2015
2014
Qualifications
Recruitment
Labor
Compensatio
Program
Training
Female
Organized
Excellent
1
and
Comprehens
oral
written
ive Exam
3-month
communication
work
skills
evaluation
Good
Sales
Talk
Seminar
Interaction
P15,000
Monthly
Training
moral
character
50 | P a g e
Male or Female
Has
sufficient
knowledge
in
inventory
management
and
Organized
Excellent
and
Comprehe
nsive
Application
Exam
letter
Interview
Medical
certificate
oral
written
NBI
training
3-month
seminars
work
Good
evaluation
15,000
Training
and
skills
moral
month
clearance
Monthly
FIFO
Seminar
character
Resume
communication
Screening
quality
assurance
ISO
Seminar
Willing to work
in early hours
Hardworking
Male or Female
Physically fit
Willing to work in
Sales
early hours
Hardworking
Comprehens
Good
background
1
sales
in
and
and
3-month
work
marketing
Excellent
ive Exam
oral
written
evaluation
Talk
Seminar
Interaction
Training
FIFO
Seminar
P15,000
Monthly
10%
Incentives
ISO
Seminar
communication
skills
Good
moral
character
51 | P a g e
Male or Female
Physically fit
Willing to work in
Stall Attendants
early hours
At
least
high
school graduate
4
12
16
20
Hardworking
Good
oral
and
Comprehens
ive Exam
1-month
work
evaluation
written
Sales
Talk
Seminar
Interaction
Training
5S+1
P9,000
Monthly
10%
incentives
Seminar
communication
skills
Good
moral
character
4.4
years of experience with corporations and has the capacity to handle agreements,
settlements, acquisitions and certifications and at least has a bit knowledge of other
business related transactions with regards to financing and/or accounting. The lawyer
must be hired during the pre-operational period to guide and would serve as the consultant
with regards to every deals, agreements, settlement and business processes that needs
to be prepared before the launching of the production. The compensation for the lawyer
shall be P30,000.
A Pharmaceutical Analysts or skincare expert is needed to be hired by the
company. The firm requires expert/analysts that has a manufacturing experience for at
least two to three years and has background practicing chemistry and other related
professions that could function as consultant and help guide for the production processes
and product formulations. The Pharmaceutical Analysts/Experts should be able to provide
any development or progress regarding the effectiveness to the current production
formulations for each variant. He should be hired in the first year of the operational period
and the compensation shall P60,000.
52 | P a g e
5 Social Responsibility
5.1
Economy
Tropical Pharmaceutical offers business with other companies, introducing a
Davao brand product and operates business provides contribution to the growth of the
economy and at the same time provides employment as a way to help the community,
helps circulate money by dealing with other business organization, and provides name
that acknowledges the work of Dabaweos.
5.2
Community
Tropical Pharmaceutical provides ready-made and all natural medicine that could
help repel mosquitoes, relieve body pains, and medicate insect bites and skin illnesses.
The company also aims to contribute to the programs held by Department of Health: (1)
Dengue Awareness Month during the month of June, (2) World Psoriasis Day for the
month of October and (3) National Skin Disease Detection and Prevention Week every
2nd week of November. The company also offers job opportunities and at the same time
helping other retailers earn money.
5.3
Environment
Tropical Pharmaceutical follows laws and provisions with regards to solid wastes
53 | P a g e
6 Financing Plan
6.1
179,886.00
122,500.00
350,000.00
652,386.00
PRE-OPERATING EXPENSES
Licenses, Permits, and Registration Fees
Trial Run
TOTAL
170,352.00
98,000.00
268,352.00
835,171.33
CONTINGENCY
TOTAL
TOTAL STARTUP AND CAPITALIZATION
6.2
176,000.00
1,936,000.00
Sourcing
Since the company is a corporation, one of its financing sources is from capital
stocks. The total amount of available capital stock is 154,800. The par value of each stock
amounts P5.00. The said available stocks, which amounts to P774,000.00, are distributed
among the nine (9) preferred stockholders while the remaining P55,000.00 will be shared
among the common stockholders. The dividends paid for the preferred stockholders will
be 40% of net income while half of the remaining will go to the common stockholders.
54 | P a g e
Stocks
Value
Ownership
4,600.00
23,000.00
15%
Subang, Nimfa
27,800.00
139,000.00
13%
Tan, Tyrone
20,200.00
101,000.00
10%
Inguillo, Norma
20,200.00
101,000.00
10%
De Leon, William
27,800.00
139,000.00
13%
4,600.00
23,000.00
15%
Baquirel, Gregorio
15,400.00
77,000.00
7%
23,200.00
116,000.00
11%
Common Stocks
11,000.00
55,000.00
5%
154,800.00
774,000.00
100%
Twenty-five percent of the total stocks are allotted for intellectual property. Thus,
such is distributed between the two originators having percentage of ownership stated in
the table above.
Loaning from the bank is another source of the companys financing. The loan will
amount to P1,162,000.00, The amount will be loans from the Bank of Philippine Islands
(BPI).
Table 10.3. Short-Term Loan
Bank
Amount
BPI
P1,162,000.00
Interest
Rate
6%
Monthly
0.5%
Years to
Pay
1
Start
January
55 | P a g e
7 Financial Plan
In this section, the companys financial plan of the company is presented. It is
supported through projected financial statements from the first to the fifth operating year,
broken down monthly in the first year. Afterwards, a financial analysis of the company is
presented to show how well the companys performance will be.
7.1
Major Assumptions
7.1.1
Assets
Office renovation and Water, Electricity and Internet Installation will be useful for
20 years.
All depreciations and amortizations will be calculated through straight line method.
Liabilities
Accounts payables for direct materials will be fully paid after 30 days. (See Section
7.10.3: Accounts Payable Management)
The long-term loan will be paid at most ten years. (See Appendix N: Depreciation,
Amortization, and Loan Schedules)
56 | P a g e
Sales
2014
2015
2016
2017
2018
25.00
26.30
27.70
29.10
30.60
87.50
91.90
96.50
101.40
106.50
100.00
105.00
110.30
115.90
121.70
175.00
183.80
193.00
202.70
212.90
200.00
210.00
220.50
231.60
243.20
130.00
136.50
143.40
150.60
158.20
110.00
115.50
121.30
127.40
133.80
230.00
241.50
253.60
266.30
279.70
The increase of prices is based on an inflation rate of 2.16% for years 2014, 2015,
2016, 2017, and 2018. (See Appendix G: Forecasted Inflation and GDP Rates)
90% of the sales transactions will be on credit and be collected after 30 days.
Expenses
Full absorption costing method is used for calculating the COGS. (See Appendix
M: Annual Cost of Goods Sold)
All costs except depreciations and amortizations rates are inflated according to the
said inflation rate. (See Appendix G: Forecasted Inflation and GDP Rates)
Salaries and Wages increase by an average of 25% per year. (See Appendix O:
Salaries and Wages Schedule)
Office rent will be P15, 600 per month. (See Section 7.8: Office Location)
Light and power rate is based on Davao Light and Power Co. charges per Kilowatthour.
Water rate is based on the Davao City Water District charges per cubic meter.
(See Appendix L: Renovation and Utilities Installation)
SSS, PhilHealth, and Pag-Ibig premium expenses are based on the SSS,
PhilHealth, and Pag-Ibig contribution schedules. (See Appendix P: SSS,
PhilHealth, and Pag-ibig Contribution Schedules)
Compensation covers only 13.5 months including bonuses to its regular workers;
daily salaries and wages per position
7.1.5
There is a 12% VAT on all product sales. (See Section 6.4.5: Price Strategies)
Interest rate of short-term loans will be 6% per annum. (See Table 10.3: ShortTerm Loan)
Desired return on capital to owners will be 20%. (See Section 10.2: Sourcing)
58 | P a g e
7.2
Financial Statements
Table 11.3. First Year Monthly Income Statement, January to June 2014
Pre-Operating
January
February
March
April
May
June
REVENUE
Inhalers (2-ml Liniment)
18,240.00
14,580.00
16,410.00
12,930.00
12,930.00
18,450.00
66,850.00
53,462.50
60,112.50
47,337.50
47,337.50
67,637.50
50,900.00
40,700.00
45,800.00
36,100.00
36,100.00
51,500.00
121,800.00
97,475.00
109,550.00
86,275.00
86,275.00
123,200.00
92,800.00
74,200.00
83,400.00
65,800.00
65,800.00
93,800.00
96,850.00
96,850.00
96,850.00
140,010.00
140,010.00
140,010.00
81,950.00
81,950.00
81,950.00
118,470.00
118,470.00
118,470.00
146,740.00
146,740.00
146,740.00
212,290.00
212,290.00
212,290.00
676,130.00
605,957.50
640,812.50
719,212.50
719,212.50
825,357.50
less: VAT
81,135.60
72,714.90
76,897.50
86,305.50
86,305.50
99,042.90
6,085.17
5,453.62
5,767.31
6,472.91
6,472.91
7,428.22
588,909.23
527,788.98
558,147.69
626,434.09
626,434.09
718,886.38
416,377.47
204,238.69
190,823.94
191,554.47
250,042.55
241,416.30
Net Sales
COST OF GOODS SOLD
Cost of Goods Manufactured
217,204.51
206,152.87
195,578.58
194,080.28
250,560.73
416,377.47
421,443.20
396,976.81
387,133.05
444,122.83
491,977.02
217,204.51
206,152.87
195,578.58
194,080.28
250,560.73
248,784.59
199,172.96
215,290.33
201,398.23
193,052.77
193,562.10
243,192.43
GROSS PROFIT
389,736.27
312,498.65
356,749.46
433,381.32
432,871.98
475,693.95
Pre-Operating
January
February
March
April
May
June
OPERATING EXPENSES
Depreciation Expense
Amortization
22,362.67
22,362.67
22,362.67
22,362.67
22,362.67
22,362.67
101,506.99
103,219.32
103,858.91
119,676.57
119,676.57
122,403.43
Rental Expense
15,600.00
15,600.00
15,600.00
15,600.00
15,600.00
15,600.00
Utilities Expense
8,150.00
8,150.00
8,150.00
8,150.00
8,150.00
8,150.00
Advertising Expense
27,045.20
24,238.30
25,632.50
28,768.50
28,768.50
33,014.30
Distribution Expense
45,326.67
39,836.67
42,581.67
55,328.33
55,328.33
63,608.33
6,060.70
6,060.70
6,060.70
6,060.70
6,060.70
6,060.70
Philhealth Contribution
1,075.00
1,075.00
1,075.00
1,075.00
1,075.00
1,075.00
Pag-ibig Contribution
1,840.00
1,840.00
1,840.00
1,840.00
1,840.00
1,840.00
237,035.99
263,706.94
251,591.07
299,232.48
286,349.28
316,601.95
152,700.28
48,791.72
105,158.39
134,148.84
146,522.70
159,092.01
5,810.00
5,339.00
4,865.65
4,389.94
3,911.84
3,431.35
146,890.28
43,452.71
100,292.74
129,758.90
142,610.86
155,660.65
44,067.08
13,035.81
30,087.82
38,927.67
42,783.26
46,698.20
102,823.19
30,416.90
70,204.92
90,831.23
99,827.60
108,962.46
Interest Expense
INCOME BEFORE TAXES
Income Tax (30%)
NET INCOME
6,687.03
-
1,381.75
-
6,687.03
6,687.03
6,687.03
6,687.03
6,687.03
18,255.51
16,360.85
17,301.94
19,418.74
19,418.74
1,381.75
15,000.00
1,381.75
-
1,381.75
15,000.00
1,381.75
-
1,381.75
15,000.00
60 | P a g e
Table 11.4. First Year Monthly Income Statement, July to December 2014
July
August
September
October
November
December
REVENUE
Inhalers (2-ml Liniment)
18,600.00
11,160.00
14,880.00
16,920.00
11,280.00
18,810.00
68,162.50
40,862.50
54,512.50
62,037.50
41,300.00
68,862.50
51,900.00
31,200.00
41,500.00
47,200.00
31,500.00
52,500.00
124,250.00
74,550.00
99,400.00
113,050.00
75,250.00
125,475.00
94,600.00
56,800.00
75,600.00
86,000.00
57,400.00
95,600.00
141,050.00
141,050.00
98,800.00
99,840.00
99,840.00
114,140.00
119,350.00
119,350.00
83,600.00
84,480.00
84,480.00
96,580.00
213,900.00
213,900.00
149,730.00
151,340.00
151,340.00
172,960.00
831,812.50
688,872.50
618,022.50
660,867.50
552,390.00
744,927.50
99,817.50
82,664.70
74,162.70
79,304.10
66,286.80
89,391.30
7,486.31
6,199.85
5,562.20
5,947.81
4,971.51
6,704.35
724,508.69
600,007.95
538,297.60
575,615.59
481,131.69
648,831.85
179,200.21
184,423.94
213,308.34
157,943.41
238,867.87
280,292.44
248,784.59
183,480.90
193,907.12
217,417.55
163,995.23
246,469.44
427,984.81
367,904.84
407,215.46
375,360.96
402,863.09
526,761.87
183,480.90
193,907.12
217,417.55
163,995.23
246,469.44
287,803.59
244,503.91
173,997.72
189,797.91
211,365.74
156,393.66
238,958.28
GROSS PROFIT
480,004.78
426,010.23
348,499.69
364,249.86
324,738.03
409,873.57
61 | P a g e
July
August
September
October
November
December
OPERATING EXPENSES
Depreciation Expense
Bad Debts Expense
Amortization
Salaries and Wages
Professional Fees Expense
Office Supplies Expense
Repairs and Maintenance
6,687.03
6,687.03
6,687.03
6,687.03
6,687.03
6,687.03
22,284.65
22,458.94
18,599.56
16,686.61
17,843.42
14,914.53
22,362.67
22,362.67
22,362.67
22,362.67
22,362.67
22,362.67
137,774.77
133,053.46
130,713.28
146,079.22
141,699.98
298,945.45
1,381.75
-
1,381.75
15,000.00
1,381.75
-
1,381.75
15,000.00
1,381.75
-
60,000.00
1,381.75
15,000.00
Rental Expense
15,600.00
15,600.00
15,600.00
15,600.00
15,600.00
15,600.00
Utilities Expense
8,150.00
8,150.00
8,150.00
8,150.00
8,150.00
8,150.00
Advertising Expense
33,272.50
27,554.90
24,720.90
26,434.70
22,095.60
29,797.10
Distribution Expense
81,800.00
70,640.00
76,220.00
97,246.67
88,786.67
100,081.67
6,060.70
6,060.70
6,060.70
6,060.70
6,060.70
6,060.70
Philhealth Contribution
1,075.00
1,075.00
1,075.00
1,075.00
1,075.00
1,075.00
Pag-ibig Contribution
1,840.00
1,840.00
1,840.00
1,840.00
1,840.00
1,840.00
338,289.06
331,864.44
313,410.88
364,604.34
333,582.82
581,895.88
141,715.72
94,145.79
35,088.80
2,948.46
2,463.16
1,975.43
1,485.26
138,767.26
91,682.63
33,113.37
(1,839.74)
41,630.18
27,504.79
9,934.01
97,137.08
64,177.84
23,179.36
Interest Expense
INCOME BEFORE TAXES
Income Tax (30%)
NET INCOME
(354.48)
(1,839.74)
(8,844.78)
992.64
(9,837.42)
(9,837.42)
(172,022.32)
497.56
(172,519.87)
(172,519.87)
62 | P a g e
Table 11.5. First Year Monthly Statement of Cash Flows, Pre-operating Period to June 2014
Pre-Operating
CASH FLOW FROM OPERATING ACTIVITIES
Cash receipts from customers
Cash paid for purchases
Cash paid for salaries and wages
Cash paid for professional fees
Cash paid for office supplies
Cash paid for repairs and maintenance
Cash paid for rental
Cash paid for utilities
Cash paid for advertising
Cash paid for distrubution
Cash paid for SSS Premium
Cash paid for PhilHealth
Cash paid for Pag-ibig
Cash paid for interest
Cash paid for taxes
Income Tax
VAT
Cash paid for Pre-Operating Expenses
Net Cash provided by Operating Activities
(268,352.00)
(268,352.00)
(652,386.00)
(652,386.00)
774,000.00
1,162,000.00
1,936,000.00
1,015,262.00
January
February
67,613.00
(454,040.23)
(101,506.99)
(1,381.75)
(27,045.20)
(45,326.67)
-
663,027.58
(254,021.49)
(103,219.32)
(1,381.75)
(15,000.00)
(15,600.00)
(8,150.00)
(24,238.30)
(39,836.67)
(6,060.70)
(1,075.00)
(1,840.00)
-
603,989.38
(148,582.39)
(103,858.91)
(1,381.75)
(15,600.00)
(8,150.00)
(25,632.50)
(42,581.67)
(6,060.70)
(1,075.00)
(1,840.00)
-
624,629.68
(302,023.46)
(119,676.57)
(1,381.75)
(15,000.00)
(15,600.00)
(8,150.00)
(28,768.50)
(55,328.33)
(6,060.70)
(1,075.00)
(1,840.00)
-
696,378.74
(232,567.75)
(119,676.57)
(1,381.75)
(15,600.00)
(8,150.00)
(28,768.50)
(55,328.33)
(6,060.70)
(1,075.00)
(1,840.00)
-
706,052.15
(153,915.00)
(122,403.43)
(1,381.75)
(15,000.00)
(15,600.00)
(8,150.00)
(33,014.30)
(63,608.33)
(6,060.70)
(1,075.00)
(1,840.00)
-
(561,687.84)
192,604.36
249,226.46
69,725.37
225,930.13
284,003.63
(94,199.19)
(94,199.19)
March
April
May
June
(94,670.19)
(94,670.19)
(95,143.54)
(95,143.54)
(95,619.26)
(95,619.26)
(96,097.35)
(96,097.35)
(96,577.84)
(96,577.84)
1,015,262.00
359,374.97
457,309.14
611,392.07
585,498.18
715,330.95
359,374.97
457,309.14
611,392.07
585,498.18
715,330.95
902,756.75
63 | P a g e
Table 11.6. First Year Monthly Statement of Cash Flows, July to December 2014
July
CASH FLOW FROM OPERATING ACTIVITIES
Cash receipts from customers
Cash paid for purchases
Cash paid for salaries and wages
Cash paid for professional fees
Cash paid for office supplies
Cash paid for repairs and maintenance
Cash paid for rental
Cash paid for utilities
Cash paid for advertising
Cash paid for distrubution
Cash paid for SSS Premium
Cash paid for PhilHealth
Cash paid for Pag-ibig
Cash paid for interest
Cash paid for taxes
Income Tax
VAT
Cash paid for Pre-Operating Expenses
Net Cash provided by Operating Activities
CASH FLOW FROM INVESTING ACTIVITIES
Cash paid for Capital Expenditures
Net Cash provided by Investing Activities
August
September
October
November
December
799,156.05
(229,256.43)
(137,774.77)
(1,381.75)
(15,600.00)
(8,150.00)
(33,272.50)
(81,800.00)
(6,060.70)
(1,075.00)
(1,840.00)
-
790,613.45
(228,776.81)
(133,053.46)
(1,381.75)
(15,000.00)
(15,600.00)
(8,150.00)
(27,554.90)
(70,640.00)
(6,060.70)
(1,075.00)
(1,840.00)
-
653,303.00
(198,650.36)
(130,713.28)
(1,381.75)
(15,600.00)
(8,150.00)
(24,720.90)
(76,220.00)
(6,060.70)
(1,075.00)
(1,840.00)
-
594,285.86
(100,403.22)
(146,079.22)
(1,381.75)
(15,000.00)
(15,600.00)
(8,150.00)
(26,434.70)
(97,246.67)
(6,060.70)
(1,075.00)
(1,840.00)
-
625,472.39
(278,238.32)
(141,699.98)
(1,381.75)
(15,600.00)
(8,150.00)
(22,095.60)
(88,786.67)
(6,060.70)
(1,075.00)
(1,840.00)
-
549,985.63
(299,650.40)
(298,945.45)
(60,000.00)
(1,381.75)
(15,000.00)
(15,600.00)
(8,150.00)
(29,797.10)
(100,081.67)
(6,060.70)
(1,075.00)
(1,840.00)
-
(215,599.84)
(502,401.90)
(435,056.85)
281,480.83
188,891.00
175,014.60
60,544.37
(287,596.43)
(97,060.73)
(97,060.73)
(97,546.03)
(97,546.03)
(98,033.76)
(98,033.76)
(98,523.93)
(98,523.93)
(99,016.55)
(99,016.55)
(99,511.63)
(270,353.37)
(369,865.00)
902,756.75
370,639.17
554,573.97
645,431.21
721,921.88
683,449.69
Cash, Ending
370,639.17
554,573.97
645,431.21
721,921.88
683,449.69
25,988.26
64 | P a g e
Table 11.7. First Year Monthly Balance Sheet, January to June 2014
Pre-Operating
January
February
March
April
May
June
ASSETS
Current Assets
Cash
Accounts Receivable
less: Allowance for Bad Debts
Inventory, Raw Materials
Inventory, Finished Goods
Total Current Assets
Non-Current Assets
Office Equipment
less: Acc. Dep., OE
Machineries & Equipments
less: Acc. Dep., M&E
Truck
less: Acc. Dep., Truck
Other Assets
Amortization of Pre-Op
Total Non-Current Assets
TOTAL ASSETS
1,015,262.00
1,015,262.00
359,374.97
602,431.83
157,659.25
217,204.51
1,336,670.56
457,309.14
539,908.13
18,255.51
87,445.56
206,152.87
1,272,560.20
611,392.07
552,708.43
16,360.85
95,319.30
195,578.58
1,438,637.53
585,498.18
624,457.49
17,301.94
225,554.21
194,080.28
1,612,288.21
715,330.95
623,516.40
19,418.74
138,198.21
250,560.73
1,708,187.56
902,756.75
715,974.80
19,418.74
50,696.92
248,784.59
1,898,794.31
179,886.00
122,500.00
350,000.00
-
179,886.00
749.53
122,500.00
2,291.67
350,000.00
3,645.83
179,886.00
1,499.05
122,500.00
4,583.33
350,000.00
7,291.67
179,886.00
2,248.58
122,500.00
6,875.00
350,000.00
10,937.50
179,886.00
2,998.10
122,500.00
9,166.67
350,000.00
14,583.33
179,886.00
3,747.63
122,500.00
11,458.33
350,000.00
18,229.17
179,886.00
4,497.15
122,500.00
13,750.00
350,000.00
21,875.00
268,352.00
920,738.00
1,936,000.00
245,989.33
891,688.31
2,228,358.87
223,626.67
862,638.62
2,135,198.81
201,264.00
833,588.93
2,272,226.45
178,901.33
804,539.23
2,416,827.45
156,538.67
775,489.54
2,483,677.10
134,176.00
746,439.85
2,645,234.16
65 | P a g e
Pre-Operating
January
February
March
April
May
June
LIABILITIES
Current Liabilities
Accounts Payables
Purchases
Rental
Utilities
SSS, PhilHealth, and Pag-ibig Payables
Interest Payables
Accrued Taxes
Income Tax
VAT
Loans Payable (Short Term)
Total Current Liabilities
Non-Current Liabilities
Loans Payable (Long Term)
Total Non-Current Liabilities
TOTAL LIABILITIES
119,996.49
15,600.00
8,150.00
8,975.70
5,810.00
15,600.00
8,150.00
8,975.70
11,149.00
50,115.29
15,600.00
8,150.00
8,975.70
16,014.66
69,881.20
15,600.00
8,150.00
8,975.70
20,404.59
15,600.00
8,150.00
8,975.70
24,316.43
15,600.00
8,150.00
8,975.70
27,747.78
1,162,000.00
1,162,000.00
44,067.08
81,135.60
1,067,800.81
1,351,535.68
57,102.90
153,850.50
973,130.62
1,227,958.72
87,190.72
230,748.00
877,987.08
1,294,781.45
126,118.39
317,053.50
782,367.83
1,348,551.21
168,901.65
403,359.00
686,270.48
1,315,573.25
215,599.84
502,401.90
589,692.64
1,368,167.86
1,162,000.00
1,351,535.68
1,227,958.72
1,294,781.45
1,348,551.21
1,315,573.25
1,368,167.86
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
102,823.19
102,823.19
102,823.19
30,416.90
133,240.09
133,240.09
70,204.92
203,445.01
203,445.01
90,831.23
294,276.24
294,276.24
99,827.60
394,103.84
394,103.84
108,962.46
503,066.30
876,823.19
2,228,358.87
907,240.09
2,135,198.81
977,445.01
2,272,226.45
1,068,276.24
2,416,827.45
1,168,103.84
2,483,677.10
1,277,066.30
2,645,234.16
STOCKHOLDERS' EQUITY
Paid-In Capital, Beg.
add: Additional Paid-In Capital
Paid-In Capital, End.
Retained Earnings, Beg.
add: Net Profit
less: Cash Dividends
less: Stock Dividends (added to Paid-in Capital)
Retained Earnings, End.
TOTAL STOCKHOLDERS' EQUITY
TOTAL LIABILITIES & STOCKHOLDER'S EQUITY
774,000.00
1,936,000.00
66 | P a g e
Table 11.8. First Year Monthly Balance Sheet, July to December 2014
July
August
September
October
November
December
ASSETS
Current Assets
Cash
Accounts Receivable
less: Allowance for Bad Debts
Inventory, Raw Materials
Inventory, Finished Goods
Total Current Assets
Non-Current Assets
Office Equipment
less: Acc. Dep., OE
Machineries & Equipments
less: Acc. Dep., M&E
Truck
less: Acc. Dep., Truck
Other Assets
Amortization of Pre-Op
Total Non-Current Assets
TOTAL ASSETS
370,639.17
721,726.20
22,284.65
199,502.47
183,480.90
1,453,064.09
554,573.97
591,500.75
22,458.94
166,353.16
193,907.12
1,483,876.05
645,431.21
528,199.11
18,599.56
130,448.03
217,417.55
1,502,896.34
721,921.88
570,233.39
16,686.61
72,907.84
163,995.23
1,512,371.72
683,449.69
475,492.88
17,843.42
211,027.63
246,469.44
1,598,596.21
25,988.26
645,886.98
14,914.53
131,636.26
287,803.59
1,076,400.55
179,886.00
5,246.68
122,500.00
16,041.67
350,000.00
25,520.83
179,886.00
5,996.20
122,500.00
18,333.33
350,000.00
29,166.67
179,886.00
6,745.73
122,500.00
20,625.00
350,000.00
32,812.50
179,886.00
7,495.25
122,500.00
22,916.67
350,000.00
36,458.33
179,886.00
8,244.78
122,500.00
25,208.33
350,000.00
40,104.17
179,886.00
8,994.30
122,500.00
27,500.00
350,000.00
43,750.00
111,813.33
717,390.16
2,170,454.25
89,450.67
688,340.47
2,172,216.52
67,088.00
659,290.78
2,162,187.11
44,725.33
630,241.08
2,142,612.80
22,362.67
601,191.39
2,199,787.61
0.00
572,141.70
1,648,542.25
67 | P a g e
July
August
September
October
November
December
LIABILITIES
Current Liabilities
Accounts Payables
Purchases
Rental
Utilities
SSS, PhilHealth, and Pag-ibig Payables
Interest Payables
Accrued Taxes
Income Tax
VAT
Loans Payable (Short Term)
Total Current Liabilities
98,749.34
15,600.00
8,150.00
8,975.70
30,696.25
21,247.15
15,600.00
8,150.00
8,975.70
33,159.41
15,600.00
8,150.00
8,975.70
35,134.84
15,600.00
8,150.00
8,975.70
36,620.10
98,749.34
15,600.00
8,150.00
8,975.70
37,612.74
15,600.00
8,150.00
8,975.70
38,110.30
41,630.18
99,817.50
492,631.91
796,250.87
69,134.97
182,482.20
395,085.88
733,835.30
79,068.98
256,644.90
297,052.11
700,626.53
79,068.98
335,949.00
198,528.18
682,891.96
79,068.98
402,235.80
99,511.63
749,904.19
79,068.98
491,627.10
(0.00)
641,532.07
796,250.87
733,835.30
700,626.53
682,891.96
749,904.19
641,532.07
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
774,000.00
202,765.03
976,765.03
503,066.30
97,137.08
600,203.38
600,203.38
64,177.84
664,381.22
664,381.22
23,179.36
687,560.58
687,560.58
(1,839.74)
685,720.84
685,720.84
(9,837.42)
675,883.42
675,883.42
(172,519.87)
270,353.37
202,765.03
30,245.15
1,374,203.38
2,170,454.25
1,438,381.22
2,172,216.52
1,461,560.58
2,162,187.11
Non-Current Liabilities
Loans Payable (Long Term)
Total Non-Current Liabilities
TOTAL LIABILITIES
STOCKHOLDERS' EQUITY
1,459,720.84
2,142,612.80
1,449,883.42
2,199,787.61
1,007,010.18
1,648,542.25
68 | P a g e
2014
2015
2016
2017
2018
REVENUE
Inhalers (2-ml Liniment)
185,190.00
246,046.50
420,403.10
543,924.00
699,060.00
678,475.00
901,539.00
1,539,368.00
1,990,279.20
2,554,296.00
516,900.00
686,490.00
1,173,040.50
1,516,435.60
1,945,739.60
1,236,550.00
1,642,988.20
2,804,676.00
3,624,681.40
4,652,290.80
941,800.00
1,094,896.60
2,136,424.50
2,761,135.20
3,543,424.00
1,405,300.00
1,866,228.00
3,186,778.20
4,119,361.80
5,287,676.80
1,189,100.00
1,579,116.00
2,695,649.90
3,484,772.20
4,472,131.20
2,130,260.00
2,830,863.00
4,830,572.80
6,242,338.30
8,012,565.90
8,283,575.00
10,848,167.30
18,786,913.00
24,282,927.70
31,167,184.30
less: VAT
994,029.00
1,301,780.08
2,254,429.56
2,913,951.32
3,740,062.12
74,552.18
97,633.51
169,082.22
218,546.35
280,504.66
7,214,993.83
9,448,753.72
16,363,401.22
21,150,430.03
27,146,617.53
Net Sales
COST OF GOODS SOLD
Cost of Goods Manufactured
2,748,489.62
-
3,263,683.45
287,803.59
5,152,534.97
442,800.89
6,398,094.96
560,393.13
7,664,468.66
696,170.42
2,748,489.62
3,551,487.04
5,595,335.86
6,958,488.09
8,360,639.08
287,803.59
442,800.89
560,393.13
696,170.42
560,902.96
2,460,686.03
3,108,686.14
5,034,942.73
6,262,317.67
7,799,736.12
GROSS PROFIT
4,754,307.80
6,340,067.57
11,328,458.50
14,888,112.36
19,346,881.40
69 | P a g e
Pre-Operating
2014
2015
2016
2017
2018
OPERATING EXPENSES
Depreciation Expense
80,244.30
57,744.30
57,744.30
57,744.30
57,744.30
203,543.48
286,915.68
488,082.65
642,820.98
825,038.81
Amortization
268,352.00
1,658,607.95
2,610,092.89
4,839,042.85
6,784,220.08
9,347,987.08
60,000.00
60,000.00
60,000.00
60,000.00
60,000.00
16,581.00
16,939.86
17,306.49
17,681.06
18,063.73
90,000.00
92,400.00
94,800.00
97,200.00
99,600.00
Rental Expense
187,200.00
191,251.59
195,390.86
191,251.59
191,251.59
Utilities Expense
97,800.00
99,916.69
102,079.20
104,288.51
106,545.63
Advertising Expense
331,343.00
433,926.69
751,476.52
971,317.11
1,246,687.37
Distribution Expense
816,785.00
1,167,148.22
1,707,651.01
2,181,806.57
2,621,084.12
72,728.40
74,302.47
75,910.60
77,553.54
79,232.04
Philhealth Contribution
12,900.00
13,179.20
13,464.43
13,755.85
14,053.57
Pag-ibig Contribution
22,080.00
22,557.88
23,046.10
23,544.89
24,054.47
3,918,165.13
5,126,375.47
8,425,995.02
11,223,184.48
14,691,342.71
836,142.66
1,213,692.11
2,902,463.48
3,664,927.88
4,655,538.69
38,110.30
798,032.37
1,213,692.11
2,902,463.48
3,664,927.88
4,655,538.69
294,668.82
427,325.14
941,225.19
1,194,955.30
1,543,019.30
503,363.55
786,366.97
1,961,238.29
2,469,972.58
3,112,519.39
Interest Expense
INCOME BEFORE TAXES
Income Tax (30%)
NET INCOME
70 | P a g e
(268,352.00)
(268,352.00)
(652,386.00)
(652,386.00)
774,000.00
1,162,000.00
1,936,000.00
1,015,262.00
2014
2015
2016
2017
(362,603.69)
(1,150,841.45)
723,311.85
(729,142.04)
(1,788,636.58)
1,980,499.61
2018
23,019,463.69
(6,366,948.62)
(6,784,220.08)
(60,000.00)
(17,681.06)
(97,200.00)
(191,596.52)
(104,104.40)
(971,317.11)
(2,181,806.57)
(77,416.63)
(13,731.56)
(23,503.32)
-
29,544,776.60
(7,659,924.56)
(9,347,987.08)
(60,000.00)
(18,063.73)
(99,600.00)
(191,251.59)
(106,357.54)
(1,246,687.37)
(2,621,084.12)
(79,092.16)
(14,028.76)
(24,012.01)
-
(1,090,178.43)
(2,594,499.38)
2,445,259.99
(1,387,179.47)
(3,335,259.74)
3,354,248.47
(1,162,000.00)
(270,353.37)
(1,432,353.37)
(410,934.86)
(410,934.86)
(917,467.29)
(917,467.29)
(1,296,550.27)
(1,296,550.27)
(1,701,813.85)
(1,701,813.85)
1,015,262.00
25,988.26
338,365.25
1,401,397.58
2,550,107.29
25,988.26
338,365.25
1,401,397.58
2,550,107.29
4,202,541.91
71 | P a g e
2014
2015
2016
2017
2018
1,015,262.00
1,015,262.00
25,988.26
645,886.98
14,914.53
131,636.26
287,803.59
1,076,400.55
338,365.25
838,088.78
19,404.00
128,234.34
442,800.89
1,728,085.26
1,401,397.58
1,453,492.49
33,562.15
191,284.95
560,393.13
3,573,006.00
2,550,107.29
1,865,106.40
43,079.38
153,832.03
696,170.42
5,222,136.76
4,202,541.91
2,394,177.93
55,286.67
140,647.36
560,902.96
7,242,983.48
179,886.00
122,500.00
350,000.00
-
179,886.00
8,994.30
122,500.00
27,500.00
350,000.00
43,750.00
179,886.00
17,988.60
122,500.00
32,500.00
350,000.00
87,500.00
179,886.00
26,982.90
122,500.00
37,500.00
350,000.00
131,250.00
179,886.00
35,977.20
122,500.00
42,500.00
350,000.00
175,000.00
179,886.00
44,971.50
122,500.00
47,500.00
350,000.00
218,750.00
268,352.00
920,738.00
1,936,000.00
0.00
572,141.70
1,648,542.25
514,397.40
2,242,482.66
456,653.10
4,029,659.10
398,908.80
5,621,045.56
341,164.50
7,584,147.98
ASSETS
Current Assets
Cash
Accounts Receivable
less: Allowance for Bad Debts
Inventory, Raw Materials
Inventory, Finished Goods
Total Current Assets
Non-Current Assets
Office Equipment
less: Acc. Dep., OE
Machineries & Equipments
less: Acc. Dep., M&E
Truck
less: Acc. Dep., Truck
Other Assets
Amortization of Pre-Op
Total Non-Current Assets
TOTAL ASSETS
72 | P a g e
Pre-Operating
2014
2015
15,600.00
8,150.00
8,975.70
38,110.30
29,887.72
15,937.63
8,326.39
9,169.96
10,362.51
1,162,000.00
1,162,000.00
79,068.98
491,627.10
(0.00)
641,532.07
1,162,000.00
774,000.00
774,000.00
2016
2017
2018
105,055.92
16,282.57
8,506.60
9,368.43
0.00
98,749.34
15,937.63
8,690.71
9,571.19
0.00
90,108.77
15,937.63
8,878.80
9,778.34
0.00
143,790.43
642,565.73
860,040.37
355,873.58
1,108,358.71
1,603,445.81
460,650.44
1,427,810.65
2,021,409.96
616,490.28
1,832,613.02
2,573,806.84
641,532.07
860,040.37
1,603,445.81
2,021,409.96
2,573,806.84
774,000.00
202,765.03
976,765.03
976,765.03
308,201.14
1,284,966.17
1,284,966.17
688,100.47
1,973,066.64
1,973,066.64
972,412.70
2,945,479.34
2,945,479.34
1,276,360.39
4,221,839.73
503,363.55
270,353.37
202,765.03
30,245.15
786,366.97
410,934.86
308,201.14
67,230.97
1,961,238.29
917,467.29
688,100.47
355,670.54
2,469,972.58
1,296,550.27
972,412.70
201,009.60
3,112,519.39
1,701,813.85
1,276,360.39
134,345.15
1,007,010.18
1,648,542.25
1,352,197.14
2,242,482.66
2,328,737.17
4,029,659.10
3,146,488.94
5,621,045.56
4,356,184.88
7,584,147.98
LIABILITIES
Current Liabilities
Accounts Payables
Purchases
Rental
Utilities
SSS, PhilHealth, and Pag-ibig Payables
Interest Payables
Accrued Taxes
Income Tax
VAT
Loans Payable (Short Term)
Total Current Liabilities
Non-Current Liabilities
Loans Payable (Long Term)
Total Non-Current Liabilities
TOTAL LIABILITIES
STOCKHOLDERS' EQUITY
Paid-In Capital, Beg.
add: Additional Paid-In Capital
Paid-In Capital, End.
Retained Earnings, Beg.
add: Net Profit
less: Cash Dividends
less: Stock Dividends (added to Paid-in Capital)
Retained Earnings, End.
TOTAL STOCKHOLDERS' EQUITY
TOTAL LIABILITIES & STOCKHOLDER'S EQUITY
774,000.00
1,936,000.00